Replies to post #63383 on Biotech Values

[DewDiligence]

Point taken––I’ll stop mentioning LLY’s LY517717 in the same breath as Apixaban and Rivaroxaban because, even in the best case (for LLY), the development program is several years behind. Regards, Dew

[DewDiligence]

LLY Formally Terminates Factor Xa Program

> LLY has not stated that it has discontinued development of LY517717…<

It’s now official. From yesterday’s CC:

http://seekingalpha.com/article/86916-eli-lilly-co-q2-2008-earnings-call-transcript?page=2

›“We’ve previously indicated that a toxicology finding had been observed in long-term animal studies with our Factor Xa Inhibitor. After completing a thorough review of the data, we have decided to halt clinical development of this compound.”‹

They still won’t say exactly what the tox problem was.